# Regulatory mechanism of O‐linked N‐acetylglucosamine protein modification on autophagy in cancer

## TL;DR

This paper explains how a protein modification called O-GlcNAcylation controls autophagy in cancer cells, helping them survive and resist treatment.

## Contribution

The paper systematically reviews the mechanisms by which O-GlcNAcylation regulates autophagy in cancer and proposes targeting this axis as a new therapeutic strategy.

## Key findings

- O-GlcNAcylation modifies key autophagy proteins like ULK1, ATG4B, and SNAP-29 to regulate autophagy stages.
- It promotes tumor adaptation and therapy resistance by remodelling autophagy.
- Combining O-GlcNAc enzyme inhibitors with autophagy modulators could overcome drug resistance in cancer.

## Abstract

O‐linked N‐acetylglucosamine protein modification (O‐GlcNAcylation) is a dynamic, nutrient‐sensitive post‐translational modification frequently upregulated in cancers. Autophagy, a lysosome‐dependent recycling pathway, plays a context‐dependent dual role in tumorigenesis and therapy resistance. Emerging evidence reveals intricate crosstalk between these two processes, positioning the O‐GlcNAcylation‐autophagy axis as a critical regulator of cancer cell adaptation.

This review systematically delineates the multidimensional mechanisms by which O‐GlcNAcylation regulates distinct stages of autophagy initiation, maturation, and fusion across various cancer types. We detail how O‐GlcNAcylation targets core autophagy machinery, including the ULK1 complex, LC3 lipidation system, and SNARE fusion proteins, and modulates key signaling hubs like mTOR and AMPK. Furthermore, we integrate this molecular regulation with the stage‐specific pro‐tumor or tumor‐suppressive functions of autophagy, highlighting how O‐GlcNAcylation remodels autophagic flux to promote metabolic reprogramming, stress survival, and therapeutic resistance.

The O‐GlcNAcylation‐autophagy axis represents a promising therapeutic target. Combining small‐molecule inhibitors of O‐GlcNAc cycling enzymes (OGT/OGA) with autophagy modulators offers a novel strategy to overcome tumor drug resistance. Future research must address the heterogeneity of this regulatory network across cancer types and developmental stages to advance precision oncology interventions.

O‐GlcNAcylation serves as a nutrient and stress sensor that dynamically regulates autophagy at multiple stages in cancer cells.It fine‐tunes autophagy initiation, maturation and fusion by modifying key proteins such as ULK1, ATG4B and SNAP‐29.Context‐dependent O‐GlcNAcylation promotes tumour adaptation and therapy resistance via autophagy remodelling.Targeting the O‐GlcNAc–autophagy axis offers a promising strategy to overcome cancer drug resistance.

O‐GlcNAcylation serves as a nutrient and stress sensor that dynamically regulates autophagy at multiple stages in cancer cells.

It fine‐tunes autophagy initiation, maturation and fusion by modifying key proteins such as ULK1, ATG4B and SNAP‐29.

Context‐dependent O‐GlcNAcylation promotes tumour adaptation and therapy resistance via autophagy remodelling.

Targeting the O‐GlcNAc–autophagy axis offers a promising strategy to overcome cancer drug resistance.

O‐GlcNAcylation serves as a nutrient and stress sensor that dynamically regulates autophagy at multiple stages in cancer cells.It fine‐tunes autophagy initiation, maturation and fusion by modifying key proteins such as ULK1, ATG4B and SNAP‐29.Context‐dependent O‐GlcNAcylation promotes tumour adaptation and therapy resistance via autophagy remodelling.Targeting the O‐GlcNAc–autophagy axis offers a promising strategy to overcome cancer drug resistance.

O‐GlcNAcylation serves as a nutrient and stress sensor that dynamically regulates autophagy at multiple stages in cancer cells.

It fine‐tunes autophagy initiation, maturation and fusion by modifying key proteins such as ULK1, ATG4B and SNAP‐29.

Context‐dependent O‐GlcNAcylation promotes tumour adaptation and therapy resistance via autophagy remodelling.

Targeting the O‐GlcNAc–autophagy axis offers a promising strategy to overcome cancer drug resistance.